These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19339025)

  • 1. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
    Martínez Marín V; Muñoz Martín AJ; Viñuela Benéitez MC; García Alfonso P; Alonso Muñoz A; Pérez Manga G
    Med Clin (Barc); 2009 Sep; 133(10):371-4. PubMed ID: 19339025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
    J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
    Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
    Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
    Ishida N; Araki K; Sakai T; Kobayashi K; Kobayashi T; Fukada I; Hosoda M; Yamamoto M; Ichinokawa K; Takahashi S; Iwase T; Ito Y; Yamashita H
    Breast Cancer; 2016 Jul; 23(4):617-23. PubMed ID: 25896598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
    Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
    Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
    Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
    Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
    Croxtall JD; McKeage K
    Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
    Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
    J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
    Ohno S; Rai Y; Iwata H; Yamamoto N; Yoshida M; Iwase H; Masuda N; Nakamura S; Taniguchi H; Kamigaki S; Noguchi S
    Ann Oncol; 2010 Dec; 21(12):2342-2347. PubMed ID: 20494961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
    J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.